Do analysts recommend ACON or CCM?

Aclarion currently has a consensus price target of $7.50, indicating a potential upside of 173.72%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Aclarion is more favorable than Concord Medical Services. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ACON or CCM?

Aclarion has higher earnings, but lower revenue than Concord Medical Services. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aclarion $80K 84.26 -$7.23M -$9.03 N/A Concord Medical Services $65.85M 0.31 -$13.27M N/A N/A

Do analysts prefer ACON or MRAI?

Aclarion currently has a consensus target price of $7.50, suggesting a potential upside of 173.72%. Given Aclarion's stronger consensus rating and higher possible upside, research analysts plainly believe Aclarion is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, ACON or MRAI?

Aclarion has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aclarion $80K 84.26 -$7.23M -$9.03 N/A Marpai $34.87M 0.55 -$28.75M -$0.87 N/A

Is ACON or MRAI more profitable?

Marpai has a net margin of -85.70% compared to Aclarion's net margin of -10,320.51%. Marpai's return on equity of 0.00% beat Aclarion's return on equity. Company Net Margins Return on Equity Return on Assets Aclarion -10,320.51% -54.41% -51.71% Marpai -85.70% N/A -100.23%

Does the media prefer ACON or MRAI?

In the previous week, Aclarion and Aclarion both had 1 articles in the media. Aclarion's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ACON or BMGL?

Aclarion presently has a consensus price target of $7.50, indicating a potential upside of 173.72%. Given Aclarion's stronger consensus rating and higher possible upside, research analysts plainly believe Aclarion is more favorable than Basel Medical Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ACON or BMGL?

Aclarion has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aclarion $80K 84.26 -$7.23M -$9.03 N/A Basel Medical Group $8.90M 1.23 -$9.50M N/A N/A

Does the media prefer ACON or BMGL?

In the previous week, Aclarion and Aclarion both had 1 articles in the media. Aclarion's average media sentiment score of 0.00 equaled Basel Medical Group'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Basel Medical Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ACON or BRTX?

Aclarion currently has a consensus target price of $7.50, indicating a potential upside of 173.72%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Aclarion is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer ACON or BRTX?

In the previous week, Aclarion and Aclarion both had 1 articles in the media. Aclarion's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ACON or ADVB?

Aclarion presently has a consensus target price of $7.50, indicating a potential upside of 173.72%. Given Aclarion's stronger consensus rating and higher probable upside, research analysts clearly believe Aclarion is more favorable than Advanced Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Aclarion (ACON) Competitors

$2.74 -0.15 (-5.19%)

Closing price 04:00 PM Eastern

Extended Trading

$2.75 +0.01 (+0.36%)

As of 07:57 PM Eastern

Compare

ACON vs. CCM, MRAI, BMGL, BRTX, and ADVB

Should you buy Aclarion stock or one of its competitors? MarketBeat compares Aclarion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aclarion include Concord Medical Services (CCM), Marpai (MRAI), Basel Medical Group (BMGL), Biorestorative Therapies (BRTX), and Advanced Biomed (ADVB). These companies are all part of the "healthcare" industry.

How does Aclarion compare to Concord Medical Services?

Aclarion (NASDAQ:ACON) and Concord Medical Services (NYSE:CCM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Aclarion has higher earnings, but lower revenue than Concord Medical Services.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	84.26	-$7.23M	-$9.03	N/A
Concord Medical Services	$65.85M	0.31	-$13.27M	N/A	N/A

In the previous week, Aclarion had 1 more articles in the media than Concord Medical Services. MarketBeat recorded 1 mentions for Aclarion and 0 mentions for Concord Medical Services. Aclarion's average media sentiment score of 0.00 equaled Concord Medical Services'average media sentiment score.

Company	Overall Sentiment
Aclarion	Neutral
Concord Medical Services	Neutral

Aclarion currently has a consensus price target of $7.50, indicating a potential upside of 173.72%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Aclarion is more favorable than Concord Medical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.5% of Aclarion shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 46.5% of Concord Medical Services shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Concord Medical Services has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Concord Medical Services' return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Concord Medical Services	N/A	N/A	N/A

Aclarion has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Concord Medical Services has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

Summary

Aclarion beats Concord Medical Services on 8 of the 13 factors compared between the two stocks.

How does Aclarion compare to Marpai?

Aclarion (NASDAQ:ACON) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Aclarion has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Marpai has a beta of 4.94, indicating that its stock price is 394% more volatile than the broader market.

Aclarion has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	84.26	-$7.23M	-$9.03	N/A
Marpai	$34.87M	0.55	-$28.75M	-$0.87	N/A

Aclarion currently has a consensus target price of $7.50, suggesting a potential upside of 173.72%. Given Aclarion's stronger consensus rating and higher possible upside, research analysts plainly believe Aclarion is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aclarion and Aclarion both had 1 articles in the media. Aclarion's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Marpai has a net margin of -85.70% compared to Aclarion's net margin of -10,320.51%. Marpai's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Marpai	-85.70%	N/A	-100.23%

7.5% of Aclarion shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Marpai beats Aclarion on 8 of the 14 factors compared between the two stocks.

How does Aclarion compare to Basel Medical Group?

Aclarion (NASDAQ:ACON) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Aclarion presently has a consensus price target of $7.50, indicating a potential upside of 173.72%. Given Aclarion's stronger consensus rating and higher possible upside, research analysts plainly believe Aclarion is more favorable than Basel Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aclarion and Aclarion both had 1 articles in the media. Aclarion's average media sentiment score of 0.00 equaled Basel Medical Group'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Basel Medical Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclarion has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	84.26	-$7.23M	-$9.03	N/A
Basel Medical Group	$8.90M	1.23	-$9.50M	N/A	N/A

Basel Medical Group has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Basel Medical Group's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Basel Medical Group	N/A	N/A	N/A

Aclarion has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

7.5% of Aclarion shares are owned by institutional investors. 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Aclarion beats Basel Medical Group on 8 of the 12 factors compared between the two stocks.

How does Aclarion compare to Biorestorative Therapies?

Aclarion (NASDAQ:ACON) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Aclarion has higher earnings, but lower revenue than Biorestorative Therapies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	84.26	-$7.23M	-$9.03	N/A
Biorestorative Therapies	$360K	28.11	-$14.24M	-$1.07	N/A

Biorestorative Therapies has a net margin of -3,088.27% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Aclarion currently has a consensus target price of $7.50, indicating a potential upside of 173.72%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Aclarion is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aclarion has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

7.5% of Aclarion shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Aclarion and Aclarion both had 1 articles in the media. Aclarion's average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aclarion beats Biorestorative Therapies on 8 of the 13 factors compared between the two stocks.

How does Aclarion compare to Advanced Biomed?

Aclarion (NASDAQ:ACON) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Aclarion presently has a consensus target price of $7.50, indicating a potential upside of 173.72%. Given Aclarion's stronger consensus rating and higher probable upside, research analysts clearly believe Aclarion is more favorable than Advanced Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aclarion has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

7.5% of Aclarion shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 27.0% of Advanced Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Aclarion had 1 more articles in the media than Advanced Biomed. MarketBeat recorded 1 mentions for Aclarion and 0 mentions for Advanced Biomed. Aclarion's average media sentiment score of 0.00 equaled Advanced Biomed'saverage media sentiment score.

Company	Overall Sentiment
Aclarion	Neutral
Advanced Biomed	Neutral

Advanced Biomed has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Advanced Biomed's return on equity of 87.74% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Advanced Biomed	N/A	87.74%	64.49%

Advanced Biomed has lower revenue, but higher earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	84.26	-$7.23M	-$9.03	N/A
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	0.99

Summary

Aclarion and Advanced Biomed tied by winning 7 of the 14 factors compared between the two stocks.

Get Aclarion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACON vs. The Competition

Export

Metric	Aclarion	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.12M	$8.99B	$6.56B	$12.24B
Dividend Yield	N/A	1.72%	2.69%	5.82%
P/E Ratio	-0.30	24.39	25.17	23.98
Price / Sales	84.26	22.53	553.76	120.62
Price / Cash	N/A	98.97	44.82	54.51
Price / Book	0.18	5.83	10.76	6.41
Net Income	-$7.23M	$174.80M	$3.56B	$337.14M
7 Day Performance	-11.90%	2.95%	1.37%	-0.48%
1 Month Performance	-14.64%	4.43%	0.81%	0.49%
1 Year Performance	-59.71%	11.90%	30.53%	28.16%

Aclarion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACON Aclarion	3.0976 of 5 stars	$2.74 -5.2%	$7.50 +173.7%	-59.4%	$7.12M	$80K	N/A	7
CCM Concord Medical Services	0.4456 of 5 stars	$4.69 +7.3%	N/A	-21.4%	$18.97M	$65.85M	N/A	970	Gap Down
MRAI Marpai	N/A	$0.65 +6.5%	N/A	-49.1%	$16.64M	$34.87M	N/A	150	Gap Up
BMGL Basel Medical Group	0.7198 of 5 stars	$0.63 +3.4%	N/A	-76.0%	$11.44M	$8.90M	N/A	36
BRTX Biorestorative Therapies	0.4337 of 5 stars	$0.35 -9.7%	N/A	-76.3%	$9.96M	$360K	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACON) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclarion (ACON) Competitors

ACON vs. CCM, MRAI, BMGL, BRTX, and ADVB

How does Aclarion compare to Concord Medical Services?

Summary

How does Aclarion compare to Marpai?

Summary

How does Aclarion compare to Basel Medical Group?

Summary

How does Aclarion compare to Biorestorative Therapies?

Summary

How does Aclarion compare to Advanced Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclarion (ACON) Competitors

ACON vs. CCM, MRAI, BMGL, BRTX, and ADVB

How does Aclarion compare to Concord Medical Services?

Which has stronger valuation & earnings, ACON or CCM?

Does the media prefer ACON or CCM?

Do analysts recommend ACON or CCM?

Do institutionals & insiders believe in ACON or CCM?

Is ACON or CCM more profitable?

Which has more risk and volatility, ACON or CCM?

Summary

How does Aclarion compare to Marpai?

Which has more risk & volatility, ACON or MRAI?

Which has better earnings & valuation, ACON or MRAI?

Do analysts prefer ACON or MRAI?

Does the media prefer ACON or MRAI?

Is ACON or MRAI more profitable?

Do insiders and institutionals have more ownership in ACON or MRAI?

Summary

How does Aclarion compare to Basel Medical Group?

Do analysts rate ACON or BMGL?

Does the media prefer ACON or BMGL?

Which has higher valuation and earnings, ACON or BMGL?

Is ACON or BMGL more profitable?

Which has more volatility and risk, ACON or BMGL?

Do insiders & institutionals have more ownership in ACON or BMGL?

Summary

How does Aclarion compare to Biorestorative Therapies?

Which has preferable valuation & earnings, ACON or BRTX?

Is ACON or BRTX more profitable?

Do analysts recommend ACON or BRTX?

Which has more risk & volatility, ACON or BRTX?

Do institutionals and insiders believe in ACON or BRTX?

Does the media prefer ACON or BRTX?

Summary

How does Aclarion compare to Advanced Biomed?

Do analysts prefer ACON or ADVB?

Which has more volatility and risk, ACON or ADVB?

Do insiders & institutionals believe in ACON or ADVB?

Does the media prefer ACON or ADVB?

Is ACON or ADVB more profitable?

Which has better earnings & valuation, ACON or ADVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools